Researchers presented data from trials of HER2-targeted therapies from Jiangsu Hengrui Medicine, Jazz Pharma, Roche, and RemeGen.

Editas, which was unable to identify a development or licensing partner for reni-cel, is focusing its resources on its in vivo pipeline.

First-in-human results for three investigational inhibitors show anti-tumor activity without unmanageable effects on blood glucose.

Due to unfavorable pharmacokinetics and the development costs of BRAF V600E and KRAS G12C mutated cancers, the firm will not advance the STARMAP trial.

NEW YORK – Candel Therapeutics on Thursday priced a public offering of common stock and pre-funded warrants that is expected to bring in $80 million in gross proceeds. The Needham, Massachusetts-based ...

SpliceBio aims to begin a study testing its protein splicing gene therapy in the first half of 2025, now that the FDA has cleared its IND.

SAN ANTONIO – In a global study involving more than 5,000 women, risk-reducing surgeries significantly improved survival and ...

SAN DIEGO – Gilead Sciences and Arcellx's autologous B-cell maturation antigen (BCMA)-directed CAR T-cell therapy ...

NEW YORK – Leapfrog Bio on Wednesday said it will move on to a Phase II trial of its bromodomain and extra-terminal domain (BET) protein inhibitor LFB-190 in lung, colon, and bladder cancer after ...

At ASH's annual meeting, a study showed the potential for this method to inform the next treatment after patients relapse on BCMA- or GPRC5D-targeted therapy.

A stem cell transplant added to Rituxan did not improve survival for MRD-negative MCL patients in their first remission ...

Imlunestrant by itself benefited those with ESR1 mutations but also had broad efficacy in ER-positive HER2-negative tumors when combined with a CDK4/6 inhibitor.